Kyrgyzstan, Ukraine, and Uzbekistan Update National Guidelines for Drug-Resistant TB Treatment to Advance National Rollout of Three-Drug, Six-Month Regimen
PRETORIA, South Africa, Sept. 18, 2023 /PRNewswire/ -- Kyrgyzstan, Ukraine, and Uzbekistan — participants in the LIFT-TB project — have updated their National Tuberculosis (TB) Clinical Guidelines to endorse the all-oral, six-month BPaL/M (bedaquiline + pretomanid + linezolid ± Moxifloxacin) regimen(s) as the national standard for treating most patients with drug-resistant tuberculosis (DR-TB).
- Launched in 2020 , LIFT-TB is a program intended to broaden adoption and scale-up of innovative TB cures.
- As part of LIFT-TB, Kyrgyzstan, Ukraine and Uzbekistan each completed operational research of the BPaL regimen.
- They have also all committed to scaling up use of the treatment for drug-resistant TB.
- "It is heartening to see countries participating in LIFT-TB emerge as leaders in scaling up access to new DR-TB treatments.